Point72 Asset Management, L.P.
Position in AVXL — Anavex Life Sciences Corp.
CIK 1603466
STAMFORD, CT
Position in AVXL
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$407,888
-$581,856 QoQ
Shares Held
157,486
-43.4% QoQ
Ownership
0.170%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#29
of 179 holders
Holding Since
Dec 2023
3 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in AVXL Over Time
Shares Held
Position Value (USD)
Derivatives in AVXL
reported options exposure · as of Dec 31, 2023CallValue
$0
CallShares
0
PutValue
$2,069,613
PutShares
222,300
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Point72 Asset Management, L.P. holds $2,243,273,342 across 172 Biotechnology names. AVXL ranks #131 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ROIV |
Roivant Sciences Ltd.
|
4,473,478 | $158,316,386 | |
| 2 | CYTK |
Cytokinetics Inc
|
1,587,712 | $135,257,185 | |
| 3 | BBIO |
BridgeBio Pharma, Inc.
|
1,525,782 | $113,640,243 | |
| 4 | AXSM |
Axsome Therapeutics, Inc.
|
416,516 | $101,950,621 | |
| 5 | LEGN |
Legend Biotech Corp
|
3,076,124 | $88,838,461 | |
| 6 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
137,029 | $73,577,721 | |
| 7 | CELC |
Celcuity Inc.
|
650,916 | $68,098,831 | |
| 8 | ACAD |
Acadia Pharmaceuticals Inc
|
2,433,168 | $61,559,150 |
All Filings in AVXL
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $407,888 | 157,486 | Shares | Defined | 2026-08-14 | |
| 2025-12-31 | $989,744 | 278,018 | Shares | Defined | 2026-02-17 | |
| 2023-12-31 | $2,069,613 | 222,300 | Put | Defined | 2024-02-14 | |
| No filing history on record for this holder in this stock. | ||||||